Table 1.

Data after after 3 wk of l-NAME treatment

	Control NSD	l-NAME	l-NAME + MMF
	(n = 5)	(n = 6)	(n = 7)
SBP, mmHg	126.2 ± 4.27	175.5 ± 3.05a	176 ± 3.6a
Plasma creatinine, mg/dl	0.30 ± 0.03	0.40 ± 0.03	0.38 ± 0.03
Proteinuria, mg/24 h	2.8 ± 1.39	12.6 ± 4.80	11.5 ± 3.87
GS index, 0–400	0	65.3 ± 7.00a,b	45.7 ± 3.81a
TI damage score, 0–5	0.5 ± 0.21	1.96 ± 0.28a	1.25 ± 0.154
CD68 + cells/mm2	3.4 ± 1.12	88.8 ± 6.93a,c	38.1 ± 5.28a
CD3 + cells/mm2	2.6 ± 1.07	75.3 ± 7.96a,d	42.5 ± 5.17a
AII + cells/mm2	0.8 ± 0.58	28.5 ± 3.51a,c	12.5 ± 1.23a

Studies done in kidney sections harvested after 3 wk of Nω-nitro-l-arginine methyl ester (l-NAME) administration in the drinking water (l-NAME group) and l-NAME plus daily mycophenolate mofetil (MMF) treatment (MMF group). Control groups received no treatment. All rats were in a normal (0.4%)-salt diet (NSD). SBP, systolic blood pressure; GS, glomerulosclerosis; TI, tubulointerstitial; AII, angiotensin II-positive. Data are means ± SE.

^aValues higher than controls (P < 0.01 or lower). Differences between l-NAME and l-NAME + MMF groups are

^bP < 0.05,

^cP < 0.001 (multigroup variance analysis), and

^dP < 0.01.